Melanoma associated peptide analogues and vaccines against melanoma
CA 2259944 C · Owner: Figdor, Carl Gustav · Inventors: Adema, Gosse Jan; Figdor, Carl Gustav
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is concerned with cancer treatment and diagnosis especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof, vaccines against melanoma tumour , infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive CTL. Usage of said peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 8, 1997 and granted June 28, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 8, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 8, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.